SPONSOR

AbbVie

Total Trials

Recruiting

Phases

Phase 2, Phase 1, Phase 2, Phase 3, Phase 3, Phase 1, Phase 2

Conditions studied: Solid Tumors Harboring MET Amplification Parkinson Disease Parkinson's Disease Multiple Myeloma Non-Small Cell Lung Cancer c-MET Major Depressive Disorder Mid Face Volume Deficit Alzheimer's Disease Hepatocellular Carcinoma

AbbVie is a US-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. The company built its early commercial foundation on adalimumab (Humira), which became the world's best-selling drug for over a decade, treating rheumatoid arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, and other immune-mediated conditions. AbbVie's clinical research now spans immunology, oncology/hematology, aesthetics, neuroscience, and eye care — driven significantly by the 2020 acquisition of Allergan.

In hematology, AbbVie's venetoclax (Venclexta) — a BCL-2 inhibitor developed with Genentech/Roche — has established itself as a cornerstone therapy in chronic lymphocytic leukemia and acute myeloid leukemia, with ongoing trials exploring combinations with targeted agents, CAR-T cells, and bispecific antibodies. The immunology pipeline post-Humira biosimilar era is focused on next-generation IL-23 inhibitors (risankizumab/Skyrizi) and JAK inhibitors (upadacitinib/Rinvoq), both of which are in Phase 3 trials across new indications including giant cell arteritis and uveitis.

AbbVie's neuroscience program includes significant investment in migraine prevention (atogepant, ubrogepant) and Parkinson's disease (levodopa-carbidopa intestinal gel continuous infusion). The aesthetics division, inherited from Allergan, runs trials on neurotoxins and dermal fillers, representing a distinct category of interventional research. AbbVie conducts trials at academic and clinical research sites globally and maintains an open innovation model through partnerships with smaller biotechs.

Frequently Asked Questions — AbbVie

What is venetoclax and for which blood cancers is AbbVie testing it?

Venetoclax (Venclexta) is a first-in-class BCL-2 inhibitor that restores programmed cell death in cancer cells that have become resistant to apoptosis. It is FDA-approved in combination with rituximab for relapsed/refractory CLL, with obinutuzumab for previously untreated CLL/SLL, and with azacitidine or decitabine for newly diagnosed AML in patients 75 years or older who cannot tolerate intensive chemotherapy. AbbVie and Genentech are jointly running Phase 3 trials testing venetoclax in additional combinations — including with ibrutinib, acalabrutinib, and CAR-T therapies — and exploring its role in other hematologic malignancies including follicular lymphoma and mantle cell lymphoma.

What immunology conditions does AbbVie study beyond rheumatoid arthritis?

AbbVie's current immunology trials extend well beyond RA. Risankizumab (Skyrizi), an IL-23p19 inhibitor, is approved and under active study in plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, with trials now expanding to ankylosing spondylitis and other spondyloarthropathies. Upadacitinib (Rinvoq), a selective JAK1 inhibitor, is approved in RA, atopic dermatitis, PsA, AS, non-radiographic axSpA, and Crohn's, with Phase 3 trials in giant cell arteritis, uveitis, and systemic lupus underway. AbbVie also has early-stage programs in systemic sclerosis and alopecia areata.

How has the Allergan acquisition changed AbbVie's clinical trial activity?

The 2020 Allergan acquisition significantly diversified AbbVie's trial portfolio beyond immunology and oncology. Allergan brought approved products in eye care (dry eye disease treatments), central nervous system (buprenorphine, muscle relaxants), aesthetics (onabotulinumtoxinA/Botox, Juvederm fillers), and women's health. Post-acquisition, AbbVie runs trials extending Botox indications (including bladder dysfunction, chronic migraine, limb spasticity), investigational eye disease therapies, and next-generation aesthetic biologics. The neuroscience portfolio now also includes CGRP receptor antagonists for migraine (atogepant) and opioid dependence programs.

AbbVie

Frequently Asked Questions — AbbVie

Clinical Trials by AbbVie

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease

A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease

A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume

A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

A Study to Evaluate Folate Receptor Alpha (FRα) Expression in Adult Participants With Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in Italy